Literature DB >> 16387840

An in vitro Shwartzman reaction-like response is augmented age-dependently in human peripheral blood mononuclear cells.

Akira Motegi1, Manabu Kinoshita, Kengo Sato, Nariyoshi Shinomiya, Satoshi Ono, Shigeaki Nonoyama, Hoshio Hiraide, Shuhji Seki.   

Abstract

A lethal human septic shock model, mouse generalized Shwartzman reaction (GSR), was elicited by two consecutive lippolysaccharide (LPS) injections (24 h apart) in which interferon-gamma (IFN-gamma) induced by interleukin (IL)-12 played a critical role in the priming phase, and tumor necrosis factor (TNF) was an important effector molecule in the second phase. We recently reported IL-12/LPS-induced mouse GSR age-dependently enhanced. We herein demonstrate that human peripheral blood mononuclear cells (PBMC) from healthy adults/elderly, cultured with IL-12 for 24 h and with LPS for an additional 24 h, produced a much larger amount of TNF (which increased age-dependently) than did PBMC without IL-12 priming. Whereas macrophages mainly produced TNF following LPS stimulation, macrophages and lymphocytes were necessary for a sufficient TNF production. IL-12-induced IFN-gamma up-regulated Toll-like receptor 4 (TLR-4) on macrophages of adults. Although the PBMC from children produced a substantial amount of IFN-gamma after IL-12 priming, the GSR response, with augmented TNF production and an up-regulated TLR-4 expression of macrophages, was not elicited by LPS stimulation. CD56+natural killer cells, CD56+T cells, and CD57+T cells (NK-T cells), which age-dependently increased in PBMC, produced much larger amounts of IFN-gamma after IL-12 priming than that of conventional CD56-CD57-T cells and also induced cocultured macrophages to produce TNF by subsequent LPS stimulation. The elder septic patients were consistently more susceptible to lethal shock with enhanced serum TNF levels than the adult patients. The NK cells, NK-T cells, and macrophages, which change proportionally or functionally with aging, might be involved in the enhanced GSR response/septic shock observed in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16387840     DOI: 10.1189/jlb.0705396

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

1.  Dynamic modulation of innate immune response by varying dosages of lipopolysaccharide (LPS) in human monocytic cells.

Authors:  Matthew C Morris; Elizabeth A Gilliam; Julia Button; Liwu Li
Journal:  J Biol Chem       Date:  2014-06-26       Impact factor: 5.157

Review 2.  How inflammation modulates central nervous system vessel activation and provides targets for intervention--a personal perspective.

Authors:  John Hallenbeck
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

3.  The effect of synthetic C-reactive protein on the in vitro immune response of human PBMCs stimulated with bacterial reagents.

Authors:  Atsushi Sato; Hiroyuki Nakashima; Manabu Kinoshita; Masahiro Nakashima; Yoshiko Ogawa; Satoshi Shono; Masami Ikarashi; Shuhji Seki
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 4.  Respiratory syncytial virus--a comprehensive review.

Authors:  Andrea T Borchers; Christopher Chang; M Eric Gershwin; Laurel J Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 5.  Antitumor immunity produced by the liver Kupffer cells, NK cells, NKT cells, and CD8 CD122 T cells.

Authors:  Shuhji Seki; Hiroyuki Nakashima; Masahiro Nakashima; Manabu Kinoshita
Journal:  Clin Dev Immunol       Date:  2011-11-29

6.  Altered immune status of circulating T lymphocytes during sepsis: children also.

Authors:  Jean-Marc Cavaillon
Journal:  Crit Care       Date:  2014-08-14       Impact factor: 9.097

7.  Molecular Mechanisms That Underlie the Dynamic Adaptation of Innate Monocyte Memory to Varying Stimulant Strength of TLR Ligands.

Authors:  Ruoxi Yuan; Shuo Geng; Liwu Li
Journal:  Front Immunol       Date:  2016-11-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.